KyleDHolenMD

Oncology • Madison, WI

Physician

Join to view full profile

Dr. Holen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Holen's full profile

Already have an account?

Office
600 Highland Ave
Madison, WI 53792
Phone+1 608-265-1700

Fax+1 608-262-1982

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1999 - 2002
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1996 - 1999
Columbia University Vagelos College of Physicians and SurgeonsClass of 1996

Certifications & Licensure

IL State Medical License 2002 - 2017
WI State Medical License 2002 - 2015

Clinical Trials

Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas Start of enrollment: 2004 Jul 01
Completed
Phase 2
Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors
Withdrawn
Phase 2
AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Start of enrollment: 2008 Nov 07
Completed
Phase 2
A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects Start of enrollment: 2009 Oct 01
Completed
Phase 1
A Study of ABT-806 in Subjects With Advanced Solid Tumor Types Start of enrollment: 2010 Nov 01
Completed
Phase 1
Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme Start of enrollment: 2013 Apr 02
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

26 citations
Comparison of Biomarker Assays for EGFR: Implications for Precision Medicine in Patients with Glioblastoma
Andrew B. Lassman, Lisa Roberts-Rapp, Sokolova Irina A, Minghao Song, Ekaterina Pestova
Clinical Cancer Research. 2019-06-01
84 citations
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicente...
Andrew B. Lassman, Martin J. van den Bent, Hui K Gan, David A. Reardon, Priya Kumthekar
Neuro-Oncology. 2019-01-01
56 citations
Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.
Hui K Gan, David A. Reardon, Andrew B. Lassman, Ryan Merrell, Martin J. van den Bent
Neuro-Oncology. 2018-05-18

Press Mentions

Phase 1/2 Interim Data on Moderna’s mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA), Presented at the 2023 ASGCT Annual MeetingMay 19th, 2023
New Skin Cancer Vaccine Cuts Risk of Relapse by 44%, Study Shows—Here’s What to KnowApril 22nd, 2023
Skin Cancer: Vaccine May Help Prevent It from ReturningApril 19th, 2023
Join now to see all

Grant Support

Phase II Trial Of Bevacizumab And Erlotinib In Advanced Biliary TumorsNational Center For Research Resources2007
Phase II Study Of Bevacizumab PLUS Erlotinib In Advanced Hepatocellular CancerNational Center For Research Resources2007
Phase II Study Of Triapine For Advanced Adenocarcinoma Of The PancreasNational Center For Research Resources2006

Professional Memberships

American Society of Clinical Oncology - ASCO
Member